Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists
These signals help pituitary cells release growth hormone
What the research actually says (and does not say) Intellectual honesty requires separating what is proven from what is plausible
By combining Sermorelin, a functional 29-amino acid fragment of endogenous Growth Hormone Releasing Hormone (GHRH), with Ipamorelin, a highly selective pentapeptide growth hormone secretagogue (GHS), this blend allows researchers to investigate enhanced secretagogue dynamics
Enhance Redox One crucial strategy for beating COVID-19 is to enhance your redox homeostasis
It supports endurance, metabolism, and recovery while ensuring safety and effectiveness